Lentitek specialises in developing manufacturing technologies for lentiviral vectors, which are essential in the delivery of CAR-T cell and gene therapies – breakthrough treatments for cancer and genetic disorders.
Lentitek has raised €830k across 1 funding round from 1 investor, most recently a round in Mar 2025. Based in Edinburgh, UK; active in Healthtech. Data as of 7 Aug 2026.
Timing: in window vs cohort gap · momentum unknown. Funding-only estimates, not predictions and not investment advice — see signals.
| Date | Stage | Amount | Investors | |
|---|---|---|---|---|
| 2025-03-11 | Other | €830k |
| Equity Gap |
| View deal → |
